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The contributions of γδ T-cells to immunity to infection or tumors critically depend on
their activation and differentiation into effectors capable of secreting cytokines and killing
infected or transformed cells.These processes are molecularly controlled by surface recep-
tors that capture key extracellular cues and convey downstream intracellular signals that
regulate γδ T-cell physiology. The understanding of how environmental signals are inte-
grated by γδ T-cells is critical for their manipulation in clinical settings. Here, we discuss
how different classes of surface receptors impact on human and murine γδT-cell differen-
tiation, activation, and expansion. In particular, we review the role of five receptor types:
the T-cell receptor (TCR), costimulatory receptors, cytokine receptors, NK receptors, and
inhibitory receptors. Some of the key players are the costimulatory receptors CD27 and
CD28, which differentially impact on pro-inflammatory subsets of γδ T-cells; the cytokine
receptors IL-2R, IL-7R, and IL-15R, which drive functional differentiation and expansion of
γδ T-cells; the NK receptor NKG2D and its contribution to γδ T-cell cytotoxicity; and the
inhibitory receptors PD-1 and BTLA that control γδ T-cell homeostasis. We discuss these
and other receptors in the context of a five-step model of receptor signaling in γδ T-cell
differentiation and activation, and discuss its implications for the manipulation of γδT-cells
in immunotherapy.
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INTRODUCTION
γδ cells endow the T-cell compartment with a rapid, innate-
like reaction to insults, which places them in the afferent phase
of the immune response. Namely, γδ T-cells are responsible for
“lymphoid stress surveillance,” i.e., sensing and responding imme-
diately to infections or non-microbial stress without the need of
clonal expansion or de novo differentiation, in synchrony with pro-
totypic innate immune responses (1). Critically, this implicates γδ
T-cells in inflammation (2), autoimmunity (3), infectious diseases
(4, 5), and tumor surveillance (6–8).
Many of the studies elucidating the physiological roles of γδ
T-cells have been performed in murine models, where a major
breakthrough has been the identification of pro-inflammatory
subsets naturally producing either IFNγ or IL-17 (9–11). More-
over, these studies have been greatly facilitated by the identification
of cell surface markers that segregate the two functional γδ T-
cell subsets: CD27, CD122, and NK1.1 mark IFNγ-producing γδ
cells,whereas their IL-17-expressing counterparts display a CD27−
CCR6+ phenotype (9–11). Moreover, the two subsets show dis-
tinct Vγ chain usage in their TCR repertoires, with a bias toward
Vγ1 among IFNγ-producing γδ cells, and an enrichment in Vγ4
and Vγ6 in IL-17-producing γδ cells (12).
In humans, γδ T-cells are primarily identified by their
Vδ chain usage, with Vδ1+ cells predominating in the thy-
mus and in peripheral tissues, while Vδ2+ cells (mostly
co-expressing a Vγ9 chain) constitute the majority of blood-
circulating γδ T-cells. Both human γδ T-cell subsets are highly
prone to secrete IFNγ, but IL-17 can be induced in highly
inflammatory conditions triggered by infections (13) or tumors
(14, 15).
In both murine and human γδ T-cells, functional responses
are initiated upon recognition of antigens that are likely induced
by stress signals and sensed by either T-cell or natural killer
receptors. Some γδT-cell populations are also particularly respon-
sive to cytokines or innate toll-like receptor (TLR) agonists (16,
17). Following proliferation and effector responses, the return
to homeostasis is controlled by inhibitory receptors. Here, we
discuss the various layers of contributions of T (TCR and cos-
timulatory/inhibitory receptors), NK, and cytokine receptors to
the activation and differentiation of effector γδ T-cell populations
in mice and humans.
SIGNAL 1: T-CELL RECEPTOR
The γδTCR complex is composed by the γδTCR itself and var-
ious CD3 chains following the stoichiometry: TCRγδCD3ε2γδζ2
in humans and TCRγδCD3ε2γ2ζ2 in mice (18). The assembly of
a γδTCR complex in thymic progenitors has immediate conse-
quences for γδ T-cell development. The “strong” signals stemming
from the γδTCR (when compared to the “weaker” pre-TCR sig-
naling) drive γδ/αβ common precursors into the γδ lineage (19,
20). These“stronger”γδTCR signals associate with increased phos-
phorylation of ERK1/2, abundant calcium release and induction
of early growth response (Egr) transcription factors (21, 22).
The TCR complex does not present intrinsic kinase activity
but the intracellular signaling is initiated after phosphorylation of
immunoreceptor tyrosine-based activation motifs (ITAMs) in the
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CD3 cytoplasmic domains by the Src-family kinases (SFKs) Lck
and Fyn (23). The recruitment of these SFKs to the TCR complex
in γδ T-cells remains obscure since these cells do not express the
CD4 or CD8 co-receptors, which have been shown, in αβ T-cells,
to be responsible for recruiting SFKs upon αβTCR ligation (23).
Nonetheless, the importance of SFKs in γδ T-cells is underscored
by the substantial phosphorylation of ERK upon inhibition of Csk,
a potent inhibitor of SFKs (24).
SFK-mediated phosphorylation of the ITAMs on CD3 chains
allows the recruitment, phospholylation, and activation of Zap70
that facilitates phosphorylation of the scaffolding proteins SLP-
76 and LAT. This lead to the formation of a supramolecular
signalosome that recruits the phospholipase PLCγ1, resulting in
propagation of downstream signaling events (22). Here again, γδ
T-cell signaling is different from αβ T-cells, since mutations on
the binding site of PLCγ1 on LAT resulted in a severe block in
murine αβ thymocyte development while γδ T-cell numbers were
only modestly reduced in the thymus, intestine, and liver, and
remained normal in the skin. Unexpectedly, a population of γδ
T-cells in the secondary lymphoid organs in these mice under-
went uncontrolled expansion and caused autoimmune pathology,
suggesting distinct functions for LAT/PLCγ1-mediated signaling
in subpopulations of γδ T-cells (21, 25).
In humans, the major γδ T-cell subset in the peripheral blood,
Vγ9Vδ2 T-cells, are uniquely and specifically reactive to self- and
foreign non-peptidic phosphorylated intermediates of isoprenoid
synthesis – “phosphoantigens” or “phosphoagonists” (P-Ags) (26–
28). These P-Ags were shown to trigger bona fide Vγ9Vδ2 TCR sig-
naling in various studies. Cipriani and colleagues showed that the
activation of Vγ9Vδ2 T-cells with the P-Ag isopentenyl pyrophos-
phate (IPP), induced rapid and persistent PKC-dependent phos-
phorylation of ERK1/2, p38 MAPK, and JNK, resulting in NF-κB
and AP-1 activation as well as the release of MIP-1α, MIP-1β,
IFN-γ, and TNF-α (29). Moreover, P-Ag stimulation and CD3-
crosslinking produced identical phosphorylation of the signaling
proteins Zap70, PI3K, LAT, ERK1/2, and p38 MAPK (30, 31); and
induced highly sustained calcium signaling in Vγ9Vδ2 T-cells (32).
Importantly, activation by P-Ags is the basis of current cancer
immunotherapy strategies involving Vγ9Vδ2 T-cells (33).
Recent work has produced some puzzling results on the role
of the γδTCR in the development of effector subsets of murine
γδ T-cells (34–36), namely, CD27+ CD122+ γδ T-cells producing
IFN-γ or CD27− CCR6+ γδ T-cells making IL-17 (9, 10). First,
Chien and co-workers showed that T10/T22-specific γδ T-cells
required thymic expression of their TCR ligand to differentiate
into IFN-γ producers, in contrast with “ligand naïve” IL-17 pro-
ducers (9). Consistent with this, TCR-dependent thymic selection
was also shown to set the functional potential of dendritic epi-
dermal T-cells (DETC) progenitors away from IL-17 production
(37). Furthermore,peripheral IL-17-producing CD27− CCR6+ γδ
T-cells were shown to expand and produce IL-17 independently
of TCR activation (38). However, a subsequent study by Chien
and collaborators demonstrated that a subset of phycoerythrin
(PE)-specific γδ T-cells produced IL-17 specifically upon TCR lig-
ation (39). Moreover, a recent study by Hayday and colleagues
suggested that an impairment in Zap70 signaling (in SKG mice)
mostly affected the development of IL-17+ rather than IFN-γ+
γδ T-cells (40). The authors further proposed that “innate-like”
γδ T-cell populations, including IL-17 producers and some sub-
sets of IFN-γ producers, receive strong TCR signals during thymic
development to become hyporesponsive to TCR stimulation in the
periphery (40). Future research should aim to resolve the appar-
ent contradictions of the available data, namely, by clarifying the
requirement on TCR ligand engagement, as well as the develop-
mental effects of manipulating distinct γδTCR signaling pathways
and their downstream (transcriptional and post-transcriptional)
mechanisms on γδ T-cell subsets.
SIGNAL 2: COSTIMULATORY RECEPTORS
A series of T-cell costimulatory receptors are known to induce
qualitative and quantitative changes that lower activation thresh-
olds, prevent “anergy” and enhance T-cell functions. Typical cos-
timulatory receptors are type I transmembrane proteins that can
be divided into two groups, based on their structural charac-
teristics: immunoglobulin (Ig) or tumor necrosis factor receptor
(TNFR) superfamilies. Ig superfamily members have a variable
Ig-like extracellular domain and a short cytoplasmic tail, whereas
TNFR family members present extracellular domains rich in six
cysteine repeats (which form disulfide bridges) and a more com-
plex cytoplasmic tail [reviewed in Ref. (41)]. These two main types
of costimulatory receptors display different modes of intracellu-
lar signaling: whereas the CD28 family members associate directly
with protein kinases (like PI3K or ITK), TNFR superfamily co-
receptors require the adaptor proteins TRAF (TNFR-associated
factor), namely TRAF2 and TRAF5, to link to downstream sig-
naling mediators (Table 1). Here, based on their specific roles
in γδ T-cells, we shall discuss CD28 (of the Ig superfamily)
and the TNFR superfamily members, CD27, CD30, and CD137
(4-1BB).
The best studied costimulatory receptor, CD28, has historically
yielded paradoxical results on γδ T-cells (46). We have recently
readdressed this issue for both human and mouse γδ T-cells. We
described that CD28 is constitutively expressed on lymphoid γδT-
cells and promotes survival and proliferation via IL-2 production.
CD28 receptor agonists enhanced γδ T-cell expansion, which was
conversely inhibited by blocking antibodies against its B7 ligands
(42). Importantly, CD28-deficient mice displayed lower (relative
to controls) numbers of total or activatedγδT-cells upon Plasmod-
ium berghei infection, and failed to expand both their IFN-γ+ and
IL-17+ subsets (42). In contrast, Hayes and colleagues reported
that both functional γδ T-cell subsets differentiated and expanded
normally in a Listeria model (80). It would be interesting to deter-
mine how variable is the dependence on CD28 costimulation for
γδ T-cell responses to distinct infectious agents.
In naïve mice, while CD28 is not required for the development
of either IFN-γ+ or IL-17+ γδT-cell subsets (80), the TNFR super-
family member CD27 is selectively implicated in the generation of
IFN-γ+ γδ T-cells (10). In fact, we showed that CD27 expres-
sion segregates IFN-γ+ (CD27+) and IL-17+ (CD27−) γδ T-cells.
Most interestingly, these phenotypes are established in the thymus,
and since embryonic stages. Based on the results from our (10) and
Chien’s (9) teams, the development of IFN-γ-producing γδ T-cells
seemingly requires strong TCR signaling and CD27 costimulation
in the thymus.
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Table 1 | Co-receptors of γδT-cells – extracellular ligands and intracellular signaling pathways.
Receptor Ligands Intracellular signaling
initiators/adaptors
Downstream signaling
pathway
Target molecules Reference
CD28 B7.1 (CD80)
B7.2 (CD86)
PI3K
ITK
Grb2
PI3K/AKT
Grb2/MEK/ERK
IL-2, NF-κB, AP-1, Bcl-xL,
NFAT
(42–45)
CD27 CD70 TRAF2
TRAF5
Siva
IKK/NF-κB
JNK
NF-kB, Ca2+, cyclinD2,
Bcl2a1, Bcl-xL
(46–49)
CD30 CD30L TRAF2
TRAF5
TRAF/IKK/IkB
Ca2+
NF-κB, IL-4, IFNγ, IL-8, CC
chemokines
(46, 50, 51)
4-1BB
(CD137)
CD137L TRAF2 NF-κB, IFNγ (52–54)
IL-2R
IL-15R
IL-2
IL-15
Jak1
Jak3
PI3K/AKT
Jak/STAT4/STAT5
MEK/ERK
STAT1
IFNγ, TNF-α, T-bet,
eomesodermin
(55–58)
IL-7R IL-7 Jak1
Jak3
STAT3 IL-17, SOCS3 (59)
IL-21R IL-21 Jak1
Jak3
STAT3 CXCL13,
CXCR5
(60)
NKG2D MIC(A–B) DAP10 PI3K/AKT NF-κB, RelB, Bcl-xL, Bcl-2 (32, 46, 61–63)
ULBP (1–6) Grb2/VAV1/SOS1
H60 PKCθ/Ca2+
MULT1
RAE1
NKp30 B7-H6
BAT3
CD3ζ cAMP/PKA CC chemokines: CCL3,
CCL4, CCL5
(64–67)
NKp44 NKp44L DAP12 Zap70/Syk (64, 68–70)
DNAM-1
(CD226)
Nectin-like-5
Nectin-2
PKC
LFA-1
Fyn
SLP-76/VAV1/ERK (71, 72)
PD-1 PD-L1 (B7-H1)
PD-L2 (B7-DC)
SHP-1
SHP-2
CK2/PTEN/PI3K/AKT
MEK/ERK
GSK-3, Bcl-xL Smad3,
Cdc25A, IFNγ, IL-2
(73–76)
BTLA HVEM SHP-1 Zap70/ERK IL-17, TNF, IL-2 (77–79)
SHP-2
Beyond its role in thymic differentiation, CD27 is critical for the
expansion of peripheral IFN-γ-producing γδ T-cells upon infec-
tion with herpes viruses or malaria parasites in mice (81). We
showed that, in the context of TCR stimulation and upon liga-
tion to CD70, CD27 signaling activates the non-canonical NF-κB
pathway and enhances the expression of anti-apoptotic and cell
cycle-related genes, thus promoting murine γδ T-cell survival and
proliferation (81).
We have also addressed the impact of CD27 costimulation
on the activation of human γδ T-cells. Administration of solu-
ble recombinant CD70 enhanced, whereas anti-CD27 (or anti-
CD70) antibodies reduced, Vγ9Vδ2 T-cell expansion in vitro (82).
Moreover, CD27 signals induced calcium fluxes and upregulated
the expression of Cyclin D2 and the anti-apoptotic gene Bcl2a1.
Given the typical IFN-γ secretion and cytotoxicity of activated
Vγ9Vδ2 T-cells (30), our work suggests that the modulation
of CD70–CD27 signals may be beneficial in the context of γδ
T-cell-based cancer immunotherapy.
Upon activation, human γδ T-cells can also express another
TNFR superfamily member, CD30 (83). CD30 signaling, which
potentiated calcium fluxes induced by TCR activation, also
enhanced pro-inflammatory cytokine production (50). Recently,
Yoshikai and colleagues compared γδ T-cell homeostasis and
response to Listeria monocytogenes in CD30-sufficient versus
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deficient mice. They demonstrated a selective depletion of IL-17-
producing Vγ6+ T-cells in mucosal tissues in the steady-state and
upon infection (84). This associated with reduced bacterial clear-
ance, which could be rescued, alongside the IL-17+ Vγ6+ T-cell
pool, by agonistic anti-CD30 antibody administration. In contrast,
Lee et al. reported that agonistic anti-CD137 (4-1BB) antibodies
promoted the expansion of IFN-γ+Vγ1+ T-cells, which protected
(in an IFN-γ-dependent manner) also from Listeria infection (52).
This study also showed that 4-1BB was expressed and functional
on activated human γδ T-cells, and its ligation upon cell transfer
protected NOD/SCID mice against Listeria infection.
Interestingly, activated Vγ9Vδ2 T-cells also express high levels
of 4-1BBL (CD137L) (85), which besides acting as a ligand for
4-1BB on T and NK-cells, may also participate in Vγ9Vδ2 T-cell
activation due to its known reverse signaling ability (86). This
may, in fact, also apply to CD70 (CD27-ligand), which is highly
induced upon phosphoantigen-mediated stimulation of Vγ9Vδ2
T-cells (82, 87). These possibilities deserve further investigation.
SIGNAL 3: CYTOKINE RECEPTORS
Interleukins are key determinants of T-cell survival, proliferation,
and differentiation. IL-7, IL-15, and IL-2 are essential for lym-
phocyte development and homeostasis; upon inflammation, other
cytokines, namely, IL-1β, IL-12, IL-18, IL-21, and IL-23, take a
central role in determining T-cell functions. Here, we review the
main contributions of homeostatic and inflammatory cytokines
specifically to γδ T-cell physiology.
IL-7 and IL-15 are seemingly the key determinants of murineγδ
T-cell development (88–90) and homeostasis (91). A recent study
that depleted IL-7 specifically from (Foxn1+) thymic epithelial
cells showed that γδ T-cells were significantly reduced in the adult
thymus and in the gut, whereas they were completely absent in the
fetal thymus and epidermis (89). In the dermis, it was also IL-7, but
not IL-15, that supported the development and survival of the res-
ident γδT-cell population (92). Conversely, in the gut, IL-15 seems
to play the primordial role in sustaining the local intraepithelial
γδ T-cell compartment (93).
Unexpectedly, IL-7 was recently reported to promote the
selective expansion of murine IL-17-producing γδ T-cells (59).
STAT3-dependent IL-7 signals allowed CD27− γδ T-cells to resist
activation-induced cell death (AICD) and undergo proliferative
responses to TCR agonists. Such an IL-7/IL-17 axis was also
reported to be required for the γδ T-cell response to viral hepatitis
infection in vivo (94). Moreover, IL-7 also seems to support the
expansion of human IL-17-producing γδ T-cells (59).
We recently assessed the functional differentiation of human
γδ thymocytes, which are>80% of the Vδ1 subtype. We observed
that IL-15 and IL-2, but not IL-7, induced the cytotoxic type 1
(IFN-γ-producing) program in functionally immature γδ thymo-
cytes (55). This was consistent with previous data on peripheral
γδ T-cells isolated from cancer patients (95). However, additional
reports on peripheral Vγ9Vδ2 T-cell cultures showed that IL-15
or IL-2 stimulation, despite efficient ERK and AKT activation,
were not sufficient to induce effector responses; these required
phosphoantigen-dependent TCR activation and downstream cal-
cium mobilization (56, 96). Unexpectedly, in our cultures of γδ
(mostly Vδ1) thymocytes, TCR stimulation was not required for
neither ERK activation nor T-bet and eomesodermin induction
and the acquisition of effector functions (55).
IL-2 and IL-15 play key roles in the peripheral expansion of
Vγ9Vδ2 T-cells in response to microbial phosphoantigens or syn-
thetic drugs like bisphosphonates (56, 97). This notwithstanding,
it is important to note, toward the therapeutic application of
Vγ9Vδ2 T-cells, that optimal effector responses seemingly require
the combination of these cytokines with TCR agonists. Thus,
recent work from Chen and colleagues demonstrated that the dif-
ferentiation of cytotoxic type 1 Vγ9Vδ2 T-cells capable of control-
ling Mycobacterium tuberculosis infection in macaques required a
phosphoantigen/IL-2 combination (98).
Effector γδ T-cell differentiation is also greatly impacted by
inflammatory cytokines, particularly IL-12 and IL-18 that typi-
cally promote IFN-γ production; and IL-1β and IL-23 that mostly
drive IL-17 production.
High expression of IL-12Rβ expression on activated murine γδ
T-cells guarantees a dominance of type 1 (IFN-γ+) over type 2
(IL-4+) effector fates (99). Type 1 differentiation is also predom-
inant in human γδ T-cells, and can be further enhanced by IL-18
(100, 101) or IL-21 (102). The induction of a type 17 program in
human γδ T-cells requires persistent stimulation with IL-23 for
neonatal Vγ9Vδ2 T-cells (15); and IL-23 and IL-1β in the pres-
ence of TGF-β for adult Vγ9Vδ2 T-cells (13, 103). In mice, IL-1β
and IL-23 are also the main drivers of abundant IL-17 produc-
tion by peripheral γδ T-cells (3, 5, 81, 104–106), although recent
data surprisingly suggest that IL-18 can replace IL-1β in combin-
ing with IL-23 to induce IL-17 expression (107). In contrast, IL-1β
upstream of IL-1R seems essential for GM-CSF production by γδ
T-cells (108).
Finally, IL-21 was recently suggested to endow human Vγ9Vδ2
T-cells with B-cell helper activity associated with a T follicular
helper cell-like phenotype (60, 109), which may impact on the
generation of high affinity antibodies against microbial infections.
SIGNAL 4: NATURAL KILLER RECEPTORS
An important key characteristic that allows the recognition of
transformed cells by γδ T-cells is the expression of a wide set of
germline-encoded receptors that were initially described in NK-
cells and hence are collectively known as NK receptors (NKRs),
including natural cytotoxicity receptors (NCRs).
The C-type lectin-like NK receptor group 2 member D
(NKG2D) is the best studied NKR in γδ T-cells. NKG2D binds
extracellularly to multiple ligands of the MIC(A–B) and ULBP
(1–6) families in humans; and to H60, MULT1, and various RAE1
molecules in mice (110). NKG2D ligands are induced upon cellu-
lar stress, for example, downstream of the DNA-damage response
pathway in tumor cells (111, 112). The biological significance of
this recognition system is underlined by the increased susceptibil-
ity of NKG2D-deficient mice to tumor development (113).
Intracellularly, NKG2D binds to DNAX-activating protein of
10 kDa (DAP10), which carries an YXNM motif that after tyrosine
phosphorylation recruits PI3K or a Grb2–Vav1–SOS1 signaling
complex (Table 1). This motif is similar to that in CD28, and
thus, NKG2D/DAP10 may provide T-cells with costimulatory sig-
nals that synergize with the ITAM-based TCR/CD3 complex (61).
However, unlike αβ T-cells but similarly to NK-cells,γδ T-cells can
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express both DAP10 and DAP12 (62). The latter contains an ITAM
motif, which after tyrosine phosphorylation recruits and activates
Syk and ZAP70. Interestingly, only murine but not human NKG2D
is able to associate with DAP12 (in addition to DAP10).
The controversy on a primary stimulatory versus costimulatory
role of NKG2D inγδT-cells has been discussed elsewhere (46,114).
Briefly, the costimulatory function of NKG2D in human Vγ9Vδ2
T-cells was supported by additive effects on TCR-mediated activa-
tion: an upregulation of cytokine production upon MICA-NKG2D
interactions (115); and an increase in intracellular calcium mobi-
lization and cytotoxic activity (32). However, other lines of evi-
dence have suggested that NKG2D signals can activate γδT-cells in
the absence of TCR engagement: NKG2D ligation can upregulate
CD69 expression in Vγ9Vδ2 T-cells to similar extent as TCR stim-
ulation (116); NKG2D but not TCR blockade can inhibit Vγ9Vδ2
T-cell cytotoxicity against various hematological tumors (117);
and murine DETC can target tumors upon recognition of NKG2D
ligands (6, 118).
Another NKR implicated in tumor cell recognition by Vγ9Vδ2
T-cells is DNAX accessory molecule-1 (DNAM-1). DNAM-1 is
an Ig-like family glycoprotein composed of a cytoplasmic domain
containing three putative sites of phosphorylation by intracellu-
lar kinases. The phosphorylation of the Ser329 by protein kinase
C (PKC) was shown to be critical for the association between
DNAM-1 and LFA-1, which recruits the Fyn Src kinase to phos-
phorylate the Tyr322 of DNAM-1, thus initiating downstream
signaling leading to SLP-76 and Vav1 phosphorylation (Table 1)
(119). Antibody-mediated DNAM-1 blockade impaired Vγ9Vδ2
T-cell cytotoxicity and IFN-γ production against hepatocellular
carcinoma lines expressing Nectin-like-5 (71).
Recently, we characterized a Vδ1+ T-cell population capable of
targeting hematological tumors resistant to fully activated Vγ9Vδ2
T-cells (120). Unexpectedly, the enhanced killer function resulted
from induced NCR expression, namely NKp30 and NKp44, which
had been previously regarded as NK-specific markers. Although
neither Vδ1+ nor Vδ2+ cells express NCRs constitutively, these can
be upregulated selectively in Vδ1+ cells by PI3K/AKT-dependent
signals provided by γc cytokines (IL-2 or IL-15) and TCR stimu-
lation. Once expressed on the cell surface, NKp30 and NKp44 can
signal via CD3ζ and DAP12, respectively (64). We further showed
that NKp30 and NKp44 are both functional in NCR+ Vδ1+ T-
cells and synergize with NKG2D to target lymphocytic leukemia
cells (120).
In sum, NKRs seem critical for tumor recognition and
deployment of the cytotoxic program that is endowed by
TCR/γc cytokine-dependent differentiation, thus defining dis-
tinct mechanisms to be integrated in γδ T-cell-mediated cancer
immunotherapy.
SIGNAL 5: INHIBITORY RECEPTORS
Beyond efficient activation and deployment of effector functions,
it is necessary to negatively regulate the T-cell response in order to
return to the homeostatic baseline. Inhibitory receptors like PD-1
or CTLA-4 are known to be critical for this contracting phase of the
T-cell response and have become major clinical targets in cancer
immunotherapy. Although γδ T-cells rarely express CTLA-4, they
can upregulate PD-1 upon activation, while they constitutively
express BTLA, and thus these two receptors may be the key to
control γδ T-cell responses.
Programed death-1 (PD-1) is absent or low expressed on circu-
lating Vγ9Vδ2 T-cells but is rapidly induced upon activation (121).
The cytoplasmic tail of PD-1 contains conserved immunoreceptor
tyrosine-based inhibitory motif (ITIM) and switch motif (ITSM),
both of which are phosphorylated to recruit negative regulators
that block Lck activity downstream of the TCR complex (122).
Moreover, PD-1 ligation can augment the activity of the protein
phosphatase and tensin homolog (PTEN), a cellular phosphatase
that inhibits PI3K/AKT signaling and thus leads to impaired sur-
vival, proliferation, and IL-2 release (123). The expression of the
ligand PD-L1 on tumor cells inhibited Vγ9Vδ2 T-cell cytotoxic-
ity and IFN-γ production (121). However, zoledronate-induced
accumulation of P-Ags in tumor cells and consequent Vγ9Vδ2
TCR activation seemed to overcome the inhibitory effect of PD-
1/PD-L1 interactions. More research is required to understand
the full extent to what PD-1 may control γδ T-cell functions and
homeostasis.
B- and T-lymphocyte attenuator (BTLA) is another inhibitory
receptor, member of the CD28 family and structurally related to
PD-1 and CTLA-4. Binding to its ligand, herpesvirus entry medi-
ator (HVEM), induces phosphorylation of the ITIM domain and
association with SH2 domain-containing protein tyrosine phos-
phatase 1 (SHP-1) and SHP-2, which leads to attenuation of cel-
lular activation and growth (124). Recent data showed that BTLA
engagement with HVEM reduced P-Ag/TCR-mediated signaling
and inhibited Vγ9Vδ2 T-cell proliferation, including in response
to lymphoma cells (77). Conversely, BTLA-HVEM blockade using
monoclonal antibodies enhanced Vγ9Vδ2 TCR signaling and may
thus have therapeutic potential for the positive manipulation of
γδ T-cells.
A detailed study on BTLA function in murine γδ T-cells has
revealed a selective involvement in the homeostasis of the IL-
17-producing CD27− γδ T-cell subset (78). Although these cells
constitutively express low levels of BTLA, it is upregulated by IL-7
stimulation and thereby limits γδ T-cell numbers. Consequently,
BTLA-deficient mice accumulated IL-17+ CD27− γδ T-cells and
were more susceptible (than wild-type controls) to dermatitis,
which could be reversed by agonist BTLA antibodies. Thus, BTLA
may be an important target for controlling pathogenic γδ T-cells
in inflammatory and autoimmune diseases.
CONCLUDING REMARKS
A multitude of surface receptors has been shown to participate
in γδ T-cell differentiation and activation. However, some cru-
cial aspects remain to be elucidated, such as the identity of most
γδTCR ligands. Most importantly, we must improve the transfer
of past and current basic research into future protocols for γδ T-
cell-based immunotherapy. In this context, some key questions are:
how to balance γδTCR activation with“exhaustion”due to chronic
stimulation? What can be achieved by manipulating the NK-like
activation mode of γδ T-cells? Which costimulatory receptors
should be modulated, and at what stages, to boost the desired γδ
T-cell responses? Which combinations of cytokines enable the best
effector γδ T-cells for each therapeutic application? Which recep-
tors are most useful to tune down or switch off pathogenic effector
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γδ T-cells? The answers to these questions must be obtained in
appropriate in vivo pre-clinical models and hopefully next in the
clinic.
For now, we would like to propose that the five types of recep-
tor signals reviewed here define five distinct layers of regulation
of γδ T-cell differentiation, activation, and function. The γδTCR
is critical for the initial stages of differentiation and for prolifera-
tive responses; both processes further require cytokine signals that
promote cell survival, proliferation, and terminal effector func-
tion. Costimulatory and inhibitory receptors control the extent of
γδ T-cell expansion, with interesting biases toward specific effec-
tor subsets. Finally, NK receptors play a decisive role in tumor cell
targeting by γδ T-cells. Thus, we believe that the recognition of
“stressed self” can be mediated by the γδTCR but also chiefly by
NK receptors like NKG2D. As such, the characterization of both
type of ligands on tumors may be critical to design protocols, select
and monitor patients, and increase the chances of efficacious γδ
T-cell-based cancer immunotherapies.
ACKNOWLEDGMENTS
We thank Daniel Correia for helpful discussions on these
topics. Our work is supported by Fundação para a Ciên-
cia e Tecnologia (SFRH/BD/84123/2012 to Sérgio T. Ribeiro;
SFRH/BPD/78135/2011 and EXPL/IMI-IMU/0170/2013 to Julie
C. Ribot) and European Research Council (StG_260352 to Bruno
Silva-Santos).
REFERENCES
1. Hayday AC. γδT cells and the lymphoid stress-surveillance response. Immunity
(2009) 31:184–96. doi:10.1016/j.immuni.2009.08.006
2. Martin B, Hirota K, Cua DJ, Stockinger B, Veldhoen M. Interleukin-17-
producing γδ T cells selectively expand in response to pathogen products and
environmental signals. Immunity (2014) 31:321–30. doi:10.1016/j.immuni.
2009.06.020
3. Sutton CE, Lalor SJ, Sweeney CM, Brereton CF, Lavelle EC, Mills KHG.
Interleukin-1 and IL-23 induce innate IL-17 production from γδ T cells,
amplifying Th17 responses and autoimmunity. Immunity (2009) 31:331–41.
doi:10.1016/j.immuni.2009.08.001
4. Ramsburg E, Tigelaar R, Craft J, Hayday A. Age-dependent requirement for
gammadelta T cells in the primary but not secondary protective immune
response against an intestinal parasite. J Exp Med (2003) 198:1403–14.
doi:10.1084/jem.20030050
5. Lockhart E, Green AM, Flynn JL. IL-17 production is dominated by gam-
madelta T cells rather than CD4 T cells during Mycobacterium tuberculosis
infection. J Immunol (2006) 177:4662–9. doi:10.4049/jimmunol.177.7.4662
6. Girardi M, Oppenheim DE, Steele CR, Lewis JM, Glusac E, Filler R, et al.
Regulation of cutaneous malignancy by gammadelta T cells. Science (2001)
294:605–9. doi:10.1126/science.1063916
7. Gao Y, Yang W, Pan M, Scully E, Girardi M, Augenlicht LH, et al. Gamma delta
T cells provide an early source of interferon gamma in tumor immunity. J Exp
Med (2003) 198:433–42. doi:10.1084/jem.20030584
8. Lança T, Costa MF, Gonçalves-Sousa N, Rei M, Grosso AR, Penido C, et al.
Protective role of the inflammatory CCR2/CCL2 chemokine pathway through
recruitment of type 1 cytotoxic γδ T lymphocytes to tumor beds. J Immunol
(2013) 190:6673–80. doi:10.4049/jimmunol.1300434
9. Jensen KDC, Su X, Shin S, Li L, Youssef S, Yamasaki S, et al. Thymic selec-
tion determines gammadelta T cell effector fate: antigen-naive cells make
interleukin-17 and antigen-experienced cells make interferon gamma. Immu-
nity (2008) 29:90–100. doi:10.1016/j.immuni.2008.04.022
10. Ribot JC, deBarros A, Pang DJ, Neves JF, Peperzak V, Roberts SJ, et al. CD27 is a
thymic determinant of the balance between interferon-gamma- and interleukin
17-producing gammadelta T cell subsets. Nat Immunol (2009) 10:427–36.
doi:10.1038/ni.1717
11. Haas JD, González FHM, Schmitz S, Chennupati V, Föhse L, Kremmer
E, et al. CCR6 and NK1.1 distinguish between IL-17A and IFN-gamma-
producing gammadelta effector T cells. Eur J Immunol (2009) 39:3488–97.
doi:10.1002/eji.200939922
12. O’Brien RL, Born WK. gammadelta T cell subsets: a link between TCR and
function? Semin Immunol (2010) 22:193–8. doi:10.1016/j.smim.2010.03.006
13. Caccamo N, La Mendola C, Orlando V, Meraviglia S, Todaro M, Stassi G, et al.
Differentiation, phenotype, and function of interleukin-17-producing human
Vgamma9Vdelta2 T cells. Blood (2011) 118:129–38. doi:10.1182/blood-2011-
01-331298
14. Wu P, Wu D, Ni C, Ye J, Chen W, Hu G, et al. γδT17 cells promote the accumu-
lation and expansion of myeloid-derived suppressor cells in human colorectal
cancer. Immunity (2014) 40:785–800. doi:10.1016/j.immuni.2014.03.013
15. Moens E, Brouwer M, Dimova T, Goldman M, Willems F, Vermijlen D. IL-23R
and TCR signaling drives the generation of neonatal Vgamma9Vdelta2 T cells
expressing high levels of cytotoxic mediators and producing IFN-gamma and
IL-17. J Leukoc Biol (2011) 89:743–52. doi:10.1189/jlb.0910501
16. Bonneville M, O’Brien RL, Born WK. Gammadelta T cell effector functions: a
blend of innate programming and acquired plasticity. Nat Rev Immunol (2010)
10:467–78. doi:10.1038/nri2781
17. Chien Y, Meyer C, Bonneville M. γδ T cells: first line of defense
and beyond. Annu Rev Immunol (2014) 32:121–55. doi:10.1146/annurev-
immunol-032713-120216
18. Siegers GM, Swamy M, Fernández-Malavé E, Minguet S, Rathmann S,
Guardo AC, et al. Different composition of the human and the mouse gam-
madelta T cell receptor explains different phenotypes of CD3gamma and
CD3delta immunodeficiencies. J Exp Med (2007) 204:2537–44. doi:10.1084/
jem.20070782102207c
19. Hayes SM, Li L, Love PE. TCR signal strength influences alpha-
beta/gammadelta lineage fate. Immunity (2005) 22:583–93. doi:10.1016/j.
immuni.2005.03.014
20. Haks MC, Lefebvre JM, Lauritsen JPH, Carleton M, Rhodes M, Miyazaki T,
et al. Attenuation of gammadeltaTCR signaling efficiently diverts thymocytes
to the alphabeta lineage. Immunity (2005) 22:595–606. doi:10.1016/j.immuni.
2005.04.003
21. Hayes SM, Shores EW, Love PE. An architectural perspective on signaling by
the pre-, alphabeta and gammadelta T cell receptors. Immunol Rev (2003)
191:28–37. doi:10.1034/j.1600-065X.2003.00011.x
22. Smith-Garvin JE,Koretzky GA,Jordan MS. T cell activation. Annu Rev Immunol
(2009) 27:591–619. doi:10.1146/annurev.immunol.021908.132706
23. Kuhns MS, Badgandi HB. Piecing together the family portrait of TCR-CD3
complexes. Immunol Rev (2012) 250:120–43. doi:10.1111/imr.12000
24. Tan YX, Manz BN, Freedman TS, Zhang C, Shokat KM, Weiss A. Inhibition
of the kinase Csk in thymocytes reveals a requirement for actin remodel-
ing in the initiation of full TCR signaling. Nat Immunol (2014) 15:186–94.
doi:10.1038/ni.2772
25. Sullivan SA, Zhu M, Bao S, Lewis CA, Ou-Yang C, Zhang W. The role of
LAT-PLCγ1 interaction in γδ T cell development and homeostasis. J Immunol
(2014) 192:2865–74. doi:10.4049/jimmunol.1302493
26. Constant P, Davodeau F, Peyrat M, Poquet Y, Puzo G, Bonneville M, et al. Stim-
ulation of human gamma delta T cells by nonpeptidic mycobacterial ligands.
Science (1994) 264:267–70. doi:10.1126/science.8146660
27. Tanaka Y, Morita CT, Nieves E, Brenner MB, Bloom BR. Natural and synthetic
non-peptide antigens recognized by human gamma delta T cells. Nature (1995)
375:155–8. doi:10.1038/375155a0
28. Gober H-J, Kistowska M, Angman L, Jeno P, Mori L, De Libero G. Human T
cell receptor γδ cells recognize endogenous mevalonate metabolites in tumor
cells. J Exp Med (2003) 197:163–8. doi:10.1084/jem.20021500
29. Cipriani B, Knowles H, Chen L, Battistini L, Brosnan CF. Involvement of
classical and novel protein kinase C isoforms in the response of human
Vγ9Vδ2 T cells to phosphate antigens. J Immunol (2002) 169:5761–70.
doi:10.4049/jimmunol.169.10.5761
30. Correia DV, D’Orey F, Cardoso BA, Lança T, Grosso AR, DeBarros A, et al.
Highly active microbial phosphoantigen induces rapid yet sustained MEK/Erk-
and PI-3K/Akt-mediated signal transduction in anti-tumor human γδ T-cells.
PLoS One (2009) 4:e5657. doi:10.1371/journal.pone.0005657
31. Nedellec S, Bonneville M, Scotet E. Human Vgamma9Vdelta2 T cells: from
signals to functions. Semin Immunol (2010) 22:199–206. doi:10.1016/j.smim.
2010.04.004
Frontiers in Immunology | T Cell Biology January 2015 | Volume 6 | Article 15 | 6
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ribeiro et al. Receptor signaling in γδT-cells
32. Nedellec S, Sabourin C, Bonneville M, Scotet E. NKG2D costimulates human
Vγ9Vδ2 T cell antitumor cytotoxicity through protein kinase Cθ-dependent
modulation of early TCR-induced calcium and transduction signals. J Immunol
(2010) 185:55–63. doi:10.4049/jimmunol.1000373
33. Gomes A, Martins D, Silva-Santos B. Targeting γδ T lymphocytes for cancer
immunotherapy from novel mechanistic insight to clinical application. Cancer
Res (2010) 70:10024–7. doi:10.1158/0008-5472.CAN-10-3236
34. Turchinovich G, Pennington D. T cell receptor signalling in γδ cell develop-
ment: strength isn’t everything. Trends Immunol (2011) 32:567–73. doi:10.
1016/j.it.2011.09.005
35. Chien Y, Zeng X, Prinz I. The natural and the inducible: interleukin (IL)-17-
producing γδ T cells. Trends Immunol (2013) 34:151–4. doi:10.1016/j.it.2012.
11.004
36. Fahl SP, Coffey F, Wiest DL. Origins of γδ T cell effector subsets: a riddle
wrapped in an enigma. J Immunol (2014) 193:4289–94. doi:10.4049/jimmunol.
1401813
37. Turchinovich G, Hayday AC. Skint-1 identifies a common molecular mech-
anism for the development of interferon-γ-secreting versus interleukin-17-
secreting γδ T cells. Immunity (2011) 35:59–68. doi:10.1016/j.immuni.2011.
04.018
38. Kapsenberg ML. Gammadelta T cell receptors without a job. Immunity (2009)
31:181–3. doi:10.1016/j.immuni.2009.08.004
39. Zeng X,Wei Y-L, Huang J, Newell EW,Yu H, Kidd BA, et al.γδT cells recognize a
microbial encoded B cell antigen to initiate a rapid antigen-specific interleukin-
17 response. Immunity (2012) 37:524–34. doi:10.1016/j.immuni.2012.06.011
40. Wencker M, Turchinovich G, Di Marco Barros R, Deban L, Jandke A, Cope
A, et al. Innate-like T cells straddle innate and adaptive immunity by altering
antigen-receptor responsiveness. Nat Immunol (2014) 15:80–7. doi:10.1038/
ni.2773
41. Duttagupta PA, Boesteanu AC, Katsikis PD. Costimulation signals for mem-
ory CD8+ T cells during viral infections. Crit Rev Immunol (2009) 29:469–86.
doi:10.1615/CritRevImmunol.v29.i6.20
42. Ribot JC, DeBarros A, Mancio-Silva L, Pamplona A, Silva-Santos B. B7-CD28
costimulatory signals control the survival and proliferation of murine and
human γδ T cells via interleukin-2 production. J Immunol (2012) 189:1202–8.
doi:10.4049/jimmunol.1200268
43. Kane LP, Andres PG, Howland KC, Abbas AK, Weiss A. Akt provides the CD28
costimulatory signal for up-regulation of IL-2 and IFN-gamma but not TH2
cytokines. Nat Immunol (2001) 2:37–44. doi:10.1038/83144
44. Takeda K, Harada Y, Watanabe R, Inutake Y, Ogawa S, Onuki K, et al. CD28
stimulation triggers NF-kappaB activation through the CARMA1-PKCtheta-
Grb2/Gads axis. Int Immunol (2008) 20:1507–15. doi:10.1093/intimm/dxn108
45. Watanabe R, Harada Y, Takeda K, Takahashi J, Ohnuki K, Ogawa S, et al.
Grb2 and Gads exhibit different interactions with CD28 and play dis-
tinct roles in CD28-mediated costimulation. J Immunol (2006) 177:1085–91.
doi:10.4049/jimmunol.177.2.1085
46. Ribot JC, Debarros A, Silva-Santos B. Searching for “signal 2”: costimu-
lation requirements of γδ T cells. Cell Mol Life Sci (2011) 68:2345–55.
doi:10.1007/s00018-011-0698-2
47. Gravestein LA, Amsen D, Boes M, Calvo CR, Kruisbeek AM, Borst J. The TNF
receptor family member CD27 signals to Jun N-terminal kinase via Traf-2.
Eur J Immunol (1998) 28:2208–16. doi:10.1002/(SICI)1521-4141(199807)28:
07<2208::AID-IMMU2208>3.0.CO;2-L
48. Denoeud J, Moser M. Role of CD27/CD70 pathway of activation in immunity
and tolerance. J Leukoc Biol (2011) 89:195–203. doi:10.1189/jlb.0610351
49. Xue L, Chu F, Cheng Y, Sun X, Borthakur A, Ramarao M, et al. Siva-1 binds
to and inhibits BCL-X(L)-mediated protection against UV radiation-induced
apoptosis. Proc Natl Acad Sci U S A (2002) 99:6925–30. doi:10.1073/pnas.
102182299
50. Biswas P, Rovere P, De Filippi C, Heltai S, Smith C, Dagna L, et al. Engagement
of CD30 shapes the secretion of cytokines by human gamma delta T cells. Eur J
Immunol (2000) 30:2172–80. doi:10.1002/1521-4141(2000)30:18<2172::AID-
IMMU2172>3.0.CO;2-5
51. Biswas P, Mantelli B, Delfanti F, Ferrarini M, Poli G, Lazzarin A. CD30 ligation
differentially affects CXCR4-dependent HIV-1 replication and soluble CD30
secretion in non-Hodgkin cell lines and in gamma delta T lymphocytes. Eur J
Immunol (2003) 33:3136–45. doi:10.1002/eji.200324344
52. Lee SJ, Kim YH, Hwang SH, Kim YI, Han IS, Vinay DS, et al. 4-1BB signal stim-
ulates the activation, expansion, and effector functions of γδ T cells in mice
and humans. Eur J Immunol (2013) 43:1839–48. doi:10.1002/eji.201242842
53. Wang C, Lin GHY, McPherson AJ, Watts TH. Immune regulation by 4-1BB
and 4-1BBL: complexities and challenges. Immunol Rev (2009) 229:192–215.
doi:10.1111/j.1600-065X.2009.00765.x
54. Jang IK, Lee ZH, Kim YJ, Kim SH, Kwon BS. Human 4-1BB (CD137) signals
are mediated by TRAF2 and activate nuclear factor-kappa B. Biochem Biophys
Res Commun (1998) 242:613–20. doi:10.1006/bbrc.1997.8016
55. Ribot JC, Ribeiro ST, Correia DV, Sousa AE, Silva-Santos B. Human thy-
mocytes are functionally immature and differentiate into cytotoxic type 1
effector T cells upon IL-2/IL-15 signaling. J Immunol (2014) 192(5):2237–43.
doi:10.4049/jimmunol.1303119
56. García VE, Jullien D, Song M, Uyemura K, Shuai K, Morita CT, et al. IL-15
enhances the response of human gamma delta T cells to nonpeptide [correc-
tion of nonpetide] microbial antigens. J Immunol (1998) 160:4322–9.
57. Li H, David Pauza C. Interplay of T-cell receptor and interleukin-2 signalling
in Vγ2Vδ2 T-cell cytotoxicity. Immunology (2011) 132:96–103. doi:10.1111/j.
1365-2567.2010.03343.x
58. Liao W, Lin J-X, Leonard WJ. Interleukin-2 at the crossroads of effec-
tor responses, tolerance, and immunotherapy. Immunity (2013) 38:13–25.
doi:10.1016/j.immuni.2013.01.004
59. Michel ML, Pang DJ, Haque SF, Potocnik AJ, Pennington DJ, Hayday AC. Inter-
leukin 7 (IL-7) selectively promotes mouse and human IL-17-producing gam-
madelta cells. Proc Natl Acad Sci U S A (2012) 109:17549–54. doi:10.1073/pnas.
1204327109
60. Bansal RR, Mackay CR, Moser B, Eberl M. IL-21 enhances the potential of
human γδ T cells to provide B-cell help. Eur J Immunol (2012) 42:110–9.
doi:10.1002/eji.201142017
61. Long EO. Versatile signaling through NKG2D. Nat Immunol (2002) 3:1119–20.
doi:10.1038/ni1202-1119
62. Lanier LL. DAP10- and DAP12-associated receptors in innate immunity.
Immunol Rev (2009) 227:150–60. doi:10.1111/j.1600-065X.2008.00720.x
63. Poggi A, Zancolli M, Boero S, Catellani S, Musso A, Zocchi MR. Differential
survival of γδT cells, αβT cells and NK cells upon engagement of NKG2D
by NKG2DL-expressing leukemic cells. Int J Cancer (2011) 129:387–96.
doi:10.1002/ijc.25682
64. Hudspeth K, Silva-Santos B, Mavilio D. Natural cytotoxicity receptors: broader
expression patterns and functions in innate and adaptive immune cells. Front
Immunol (2013) 4:69. doi:10.3389/fimmu.2013.00069
65. Brandt CS, Baratin M,Yi EC, Kennedy J, Gao Z, Fox B, et al. The B7 family mem-
ber B7-H6 is a tumor cell ligand for the activating natural killer cell receptor
NKp30 in humans. J Exp Med (2009) 206:1495–503. doi:10.1084/jem.20090681
66. Martinet L, Jean C, Dietrich G, Fournié J-J, Poupot R. PGE2 inhibits natural
killer and gamma delta T cell cytotoxicity triggered by NKR and TCR through a
cAMP-mediated PKA type I-dependent signaling. Biochem Pharmacol (2010)
80:838–45. doi:10.1016/j.bcp.2010.05.002
67. Hudspeth K, Fogli M, Correia DV, Mikulak J, Roberto A, Della Bella S, et al.
Engagement of NKp30 on Vδ1 T cells induces the production of CCL3,
CCL4, and CCL5 and suppresses HIV-1 replication. Blood (2012) 119:4013–6.
doi:10.1182/blood-2011-11-390153
68. Baychelier F, Sennepin A, Ermonval M, Dorgham K, Debré P, Vieillard V. Iden-
tification of a cellular ligand for the natural cytotoxicity receptor NKp44. Blood
(2013) 122:2935–42. doi:10.1182/blood-2013-03-489054
69. Vieillard V, Baychelier F, Debré P. NKp44L: a new tool for fighting cancer.
Oncoimmunology (2014) 3:e27988. doi:10.4161/onci.27988
70. McVicar DW, Taylor LS, Gosselin P, Willette-Brown J, Mikhael AI, Geahlen RL,
et al. DAP12-mediated signal transduction in natural killer cells. A dominant
role For The Syk protein-tyrosine kinase. J Biol Chem (1998) 273:32934–42.
doi:10.1074/jbc.273.49.32934
71. Toutirais O, Cabillic F, Le Friec G, Salot S, Loyer P, Le Gallo M, et al. DNAX
accessory molecule-1 (CD226) promotes human hepatocellular carcinoma
cell lysis by Vgamma9Vdelta2 T cells. Eur J Immunol (2009) 39:1361–8.
doi:10.1002/eji.200838409
72. Long EO,Kim HS,Liu D,Peterson ME,Rajagopalan S. Controlling natural killer
cell responses: integration of signals for activation and inhibition. Annu Rev
Immunol (2013) 31:227–58. doi:10.1146/annurev-immunol-020711-075005
www.frontiersin.org January 2015 | Volume 6 | Article 15 | 7
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ribeiro et al. Receptor signaling in γδT-cells
73. Parry RV, Chemnitz JM, Frauwirth KA, Lanfranco AR, Braunstein I, Kobayashi
SV, et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mech-
anisms. Mol Cell Biol (2005) 25:9543–53. doi:10.1128/MCB.25.21.9543-9553.
2005
74. Chemnitz JM, Parry RV, Nichols KE, June CH, Riley JL. SHP-1 and SHP-2 asso-
ciate with immunoreceptor tyrosine-based switch motif of programmed death
1 upon primary human T cell stimulation, but only receptor ligation prevents T
cell activation. J Immunol (2004) 173:945–54. doi:10.4049/jimmunol.173.2.945
75. Patsoukis N, Li L, Sari D, Petkova V, Boussiotis VA. PD-1 increases PTEN phos-
phatase activity while decreasing PTEN protein stability by inhibiting CK2.
Mol Cell Biol (2013) 33:3091–8. doi:10.1128/MCB.00319-13
76. Patsoukis N, Brown J, Petkova V, Liu F, Li L, Boussiotis VA. Selective effects of
PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle
and inhibit T cell proliferation. Sci Signal (2012) 5:ra46. doi:10.1126/scisignal.
2002796
77. Gertner-dardenne J, Fauriat C, Orlanducci F, Thibult M, Pastor S, Fitzgibbon
J, et al. The co-receptor BTLA negatively regulates human Vγ9Vδ2 T-cell pro-
liferation: a potential way of immune escape for lymphoma cells. Blood (2013)
122:922–31. doi:10.1182/blood-2012-11-464685
78. Bekiaris V, Sedý JR, Macauley MG, Rhode-Kurnow A, Ware CF. The inhibitory
receptor BTLA controls γδ T cell homeostasis and inflammatory responses.
Immunity (2013) 39:1082–94. doi:10.1016/j.immuni.2013.10.017
79. Watanabe N, Gavrieli M, Sedy JR, Yang J, Fallarino F, Loftin SK, et al. BTLA is
a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat
Immunol (2003) 4:670–9. doi:10.1038/ni944
80. Laird RM, Wolf BJ, Princiotta MF, Hayes SM. γδ T cells acquire effector fates
in the thymus and differentiate into cytokine-producing effectors in a Listeria
model of infection independently of CD28 costimulation. PLoS One (2013)
8:e63178. doi:10.1371/journal.pone.0063178
81. Ribot JC, Chaves-Ferreira M, D’Orey F, Wencker M, Gonçalves-Sousa N, Decalf
J, et al. Cutting edge: adaptive versus innate receptor signals selectively control
the pool sizes of murine IFN-γ- or IL-17-producing γδ T cells upon infection.
J Immunol (2010) 185:6421–5. doi:10.4049/jimmunol.1002283
82. DeBarros A, Chaves-Ferreira M, D’Orey F, Ribot JC, Silva-Santos B. CD70-
CD27 interactions provide survival and proliferative signals that regulate T cell
receptor-driven activation of human gammadelta peripheral blood lympho-
cytes. Eur J Immunol (2011) 41:195–201. doi:10.1002/eji.201040905
83. Ferrarini M, Delfanti F, Gianolini M, Rizzi C,Alfano M, Lazzarin A, et al. NF-κB
modulates sensitivity to apoptosis, proinflammatory and migratory potential
in short- versus long-term cultured human γδ lymphocytes. J Immunol (2008)
181:5857–64. doi:10.4049/jimmunol.181.9.5857
84. Sun X, Shibata K, Yamada H, Guo Y, Muta H, Podack ER, et al. CD30L/CD30
is critical for maintenance of IL-17A-producing γδ T cells bearing Vγ6 in
mucosa-associated tissues in mice. Mucosal Immunol (2013) 6:1191–201.
doi:10.1038/mi.2013.18
85. Maniar A, Zhang X, Lin W, Gastman BR, Pauza CD, Strome SE, et al.
Human gammadelta T lymphocytes induce robust NK cell-mediated anti-
tumor cytotoxicity through CD137 engagement. Blood (2010) 116:1726–33.
doi:10.1182/blood-2009-07-234211
86. Shao Z, Schwarz H. CD137 ligand, a member of the tumor necrosis factor
family, regulates immune responses via reverse signal transduction. J Leukoc
Biol (2011) 89:21–9. doi:10.1189/jlb.0510315
87. Brandes M, Willimann K, Lang AB, Nam K-H, Jin C, Brenner MB, et al. Flexi-
ble migration program regulates gamma delta T-cell involvement in humoral
immunity. Blood (2003) 102:3693–701. doi:10.1182/blood-2003-04-1016
88. Malissen M,Pereira P,Gerber DJ,Malissen B, DiSanto JP. The common cytokine
receptor gamma chain controls survival of gamma/delta T cells. J Exp Med
(1997) 186:1277–85. doi:10.1084/jem.186.8.1277
89. Shitara S, Hara T, Liang B, Wagatsuma K, Zuklys S, Holländer GA, et al. IL-
7 produced by thymic epithelial cells plays a major role in the development
of thymocytes and TCRγδ+ intraepithelial lymphocytes. J Immunol (2013)
190:6173–9. doi:10.4049/jimmunol.1202573
90. He YW, Malek TR. Interleukin-7 receptor alpha is essential for the develop-
ment of gamma delta + T cells, but not natural killer cells. J Exp Med (1996)
184:289–93. doi:10.1084/jem.184.1.289
91. Baccala R, Witherden D, Gonzalez-Quintial R, Dummer W, Surh CD, Havran
WL, et al. Gamma delta T cell homeostasis is controlled by IL-7 and IL-
15 together with subset-specific factors. J Immunol (2005) 174:4606–12.
doi:10.4049/jimmunol.174.8.4606
92. Sumaria N, Roediger B, Ng LG, Qin J, Pinto R, Cavanagh LL, et al. Cutaneous
immunosurveillance by self-renewing dermal gammadelta T cells. J Exp Med
(2011) 208:505–18. doi:10.1084/jem.20101824
93. Zhao H, Nguyen H, Kang J. Interleukin 15 controls the generation of the
restricted T cell receptor repertoire of gamma delta intestinal intraepithelial
lymphocytes. Nat Immunol (2005) 6:1263–71. doi:10.1038/ni1267
94. Hou L, Jie Z, Desai M, Liang Y, Soong L, Wang T, et al. Early IL-17 production
by intrahepatic T cells is important for adaptive immune responses in viral
hepatitis. J Immunol (2013) 190:621–9. doi:10.4049/jimmunol.1201970
95. Yamaguchi T, Suzuki Y, Katakura R, Ebina T, Yokoyama J, Fujimiya Y.
Interleukin-15 effectively potentiates the in vitro tumor-specific activity
and proliferation of peripheral blood γδT cells isolated from glioblas-
toma patients. Cancer Immunol Immunother (1998) 47:97–103. doi:10.1007/
s002620050509
96. Li H, Pauza CD. HIV envelope-mediated, CCR5/α4β7-dependent killing of
CD4-negative γδ T cells which are lost during progression to AIDS. Blood
(2011) 118:5824–31. doi:10.1182/blood-2011-05-356535
97. Casetti R,Perretta G,Taglioni A,Mattei M,ColizziV,Dieli F, et al. Drug-induced
expansion and differentiation of Vgamma9Vdelta2 T cells in vivo: the role of
exogenous IL-2. J Immunol (2005) 175:1593–8. doi:10.4049/jimmunol.175.3.
1593
98. Chen CY, Yao S, Huang D, Wei H, Sicard H, Zeng G, et al. Phosphoanti-
gen/IL2 expansion and differentiation of Vγ2Vδ2 T cells increase resistance
to tuberculosis in nonhuman primates. PLoS Pathog (2013) 9:e1003501.
doi:10.1371/journal.ppat.1003501
99. Yin Z, Zhang DH, Welte T, Bahtiyar G, Jung S, Liu L, et al. Dominance of IL-12
over IL-4 in gamma delta T cell differentiation leads to default production of
IFN-gamma: failure to down-regulate IL-12 receptor beta 2-chain expression.
J Immunol (2000) 164:3056–64. doi:10.4049/jimmunol.164.6.3056
100. Li W, Kubo S, Okuda A, Yamamoto H, Ueda H, Tanaka T, et al. Effect of IL-
18 on expansion of gammadelta T cells stimulated by zoledronate and IL-2. J
Immunother (2010) 33:287–96. doi:10.1097/CJI.0b013e3181c80ffa
101. Tsuda J, Li W, Yamanishi H, Yamamoto H, Okuda A, Kubo S, et al. Involvement
of CD56brightCD11c+ cells in IL-18-mediated expansion of human γδ T cells.
J Immunol (2011) 186:2003–12. doi:10.4049/jimmunol.1001919
102. Thedrez A, Harly C, Morice A, Salot S, Bonneville M, Scotet E. IL-21-mediated
potentiation of antitumor cytolytic and proinflammatory responses of human
V gamma 9V delta 2 T cells for adoptive immunotherapy. J Immunol (2009)
182:3423–31. doi:10.4049/jimmunol.0803068
103. Ness-Schwickerath KJ, Jin C, Morita CT. Cytokine requirements for the
differentiation and expansion of IL-17A- and IL-22-producing human
Vgamma2Vdelta2 T cells. J Immunol (2010) 184:7268–80. doi:10.4049/
jimmunol.1000600
104. Duan J, Chung H, Troy E, Kasper DL. Microbial colonization drives expansion
of IL-1 receptor 1-expressing and IL-17-producing gamma/delta T cells. Cell
Host Microbe (2010) 7:140–50. doi:10.1016/j.chom.2010.01.005
105. Shibata K, Yamada H, Hara H, Kishihara K, Yoshikai Y. Resident Vdelta1+
gammadelta T cells control early infiltration of neutrophils after Escherichia
coli infection via IL-17 production. J Immunol (2007) 178:4466–72. doi:10.
4049/jimmunol.178.7.4466
106. Riol-Blanco L, Lazarevic V, Awasthi A, Mitsdoerffer M, Wilson BS, Crox-
ford A, et al. IL-23 receptor regulates unconventional IL-17-producing T cells
that control bacterial infections. J Immunol (2010) 184:1710–20. doi:10.4049/
jimmunol.0902796
107. Lalor SJ, Dungan LS, Sutton CE, Basdeo SA, Fletcher JM, Mills KHG. Caspase-
1-processed cytokines IL-1beta and IL-18 promote IL-17 production by gam-
madelta and CD4 T cells that mediate autoimmunity. J Immunol (2011)
186:5738–48. doi:10.4049/jimmunol.1003597
108. Lukens JR, Barr MJ, Chaplin DD, Chi H, Kanneganti T-D. Inflammasome-
derived IL-1β regulates the production of GM-CSF by CD4(+) T cells and γδ
T cells. J Immunol (2012) 188:3107–15. doi:10.4049/jimmunol.1103308
109. Caccamo N, Todaro M, La Manna MP, Sireci G, Stassi G, Dieli F. IL-21 regu-
lates the differentiation of a human γδ T cell subset equipped with B cell helper
activity. PLoS One (2012) 7:e41940. doi:10.1371/journal.pone.0041940
110. Eagle RA, Trowsdale J. Promiscuity and the single receptor: NKG2D. Nat Rev
Immunol (2007) 7:737–44. doi:10.1038/nri2144
111. Gasser S, Orsulic S, Brown EJ, Raulet DH. The DNA damage pathway regu-
lates innate immune system ligands of the NKG2D receptor. Nature (2005)
436:1186–90. doi:10.1038/nature03884
Frontiers in Immunology | T Cell Biology January 2015 | Volume 6 | Article 15 | 8
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ribeiro et al. Receptor signaling in γδT-cells
112. Champsaur M, Lanier LL. Effect of NKG2D ligand expression on host immune
responses. Immunol Rev (2010) 235:267–85. doi:10.1111/j.0105-2896.2010.
00893.x
113. Guerra N, Tan YX, Joncker NT, Choy A, Gallardo F, Xiong N, et al. NKG2D-
deficient mice are defective in tumor surveillance in models of spontaneous
malignancy. Immunity (2008) 28:571–80. doi:10.1016/j.immuni.2008.02.016
114. Correia DV, Lopes A, Silva-Santos B. Tumor cell recognition by γδ T lympho-
cytes: T-cell receptor vs. NK-cell receptors. Oncoimmunology (2013) 2:e22892.
doi:10.4161/onci.22892
115. Das H, Groh V, Kuijl C, Sugita M, Morita CT, Spies T, et al. MICA engage-
ment by human Vgamma2Vdelta2 T cells enhances their antigen-dependent
effector function. Immunity (2001) 15:83–93. doi:10.1016/S1074-7613(01)
00168-6
116. Rincon-Orozco B, Kunzmann V, Wrobel P, Kabelitz D, Steinle A, Herrmann
T. Activation of V gamma 9V delta 2 T cells by NKG2D. J Immunol (2005)
175:2144–51. doi:10.4049/jimmunol.175.4.2144
117. Lança T, Correia DV, Moita CF, Raquel H, Neves-Costa A, Ferreira C,
et al. The MHC class Ib protein ULBP1 is a nonredundant determinant of
leukemia/lymphoma susceptibility to gammadelta T-cell cytotoxicity. Blood
(2010) 115:2407–11. doi:10.1182/blood-2009-08-237123
118. Nitahara A, Shimura H, Ito A, Tomiyama K, Ito M, Kawai K. NKG2D ligation
without T cell receptor engagement triggers both cytotoxicity and cytokine pro-
duction in dendritic epidermal T cells. J Invest Dermatol (2006) 126:1052–8.
doi:10.1038/sj.jid.5700112
119. De Andrade LF, Smyth MJ, Martinet L. DNAM-1 control of natural killer cells
functions through nectin and nectin-like proteins. Immunol Cell Biol (2014)
92:237–44. doi:10.1038/icb.2013.95
120. Correia DV, Fogli M, Hudspeth K, da Silva MG, Mavilio D, Silva-Santos B.
Differentiation of human peripheral blood Vδ1+ T cells expressing the natural
cytotoxicity receptor NKp30 for recognition of lymphoid leukemia cells. Blood
(2011) 118:992–1001. doi:10.1182/blood-2011-02-339135
121. Iwasaki M, Tanaka Y, Kobayashi H, Murata-Hirai K, Miyabe H, Sugie T,
et al. Expression and function of PD-1 in human γδ T cells that recognize
phosphoantigens. Eur J Immunol (2011) 41:345–55. doi:10.1002/eji.201040959
122. Kulpa DA, Lawani M, Cooper A, PeretzY,Ahlers J, Sékaly R-P. PD-1 coinhibitory
signals: the link between pathogenesis and protection. Semin Immunol (2013)
25:219–27. doi:10.1016/j.smim.2013.02.002
123. Pedoeem A, Azoulay-Alfaguter I, Strazza M, Silverman GJ, Mor A. Pro-
grammed death-1 pathway in cancer and autoimmunity. Clin Immunol (2014)
153:145–52. doi:10.1016/j.clim.2014.04.010
124. McGrath MM, Najafian N. The role of coinhibitory signaling pathways in
transplantation and tolerance. Front Immunol (2012) 3:47. doi:10.3389/fimmu.
2012.00047
Conflict of Interest Statement: Bruno Silva-Santos is a co-founder and share holder
of LymphAct S.A. The other co-authors declare that the research was conducted in
the absence of any commercial or financial relationships that could be construed as
a potential conflict of interest.
Received: 21 October 2014; accepted: 08 January 2015; published online: 26 January
2015.
Citation: Ribeiro ST, Ribot JC and Silva-Santos B (2015) Five layers of receptor
signaling in γ δ T-cell differentiation and activation. Front. Immunol. 6:15. doi:
10.3389/fimmu.2015.00015
This article was submitted to T Cell Biology, a section of the journal Frontiers in
Immunology.
Copyright © 2015 Ribeiro, Ribot and Silva-Santos. This is an open-access article dis-
tributed under the terms of the Creative Commons Attribution License (CC BY). The
use, distribution or reproduction in other forums is permitted, provided the original
author(s) or licensor are credited and that the original publication in this journal is cited,
in accordance with accepted academic practice. No use, distribution or reproduction is
permitted which does not comply with these terms.
www.frontiersin.org January 2015 | Volume 6 | Article 15 | 9
